Monday, 23 April 2018 - 2:54
  • it
  • de
  • en
  • fr

Companies

Pharma sector growth slowing down in US

Iqvia Consulting has reported that spending on prescription medicines was $457bn in the US in 2017, that is as little as +0.6% vs 2016, which means that growth has significantly  slowed down in the sector as compared to the last…

Teva terminates JV with P&G

Teva Pharmaceutical has announced it has terminated the PGT Healthcare with Procter & Gamble, established in 2011 in order to market OTCs (Over-The-Counter drugs). The decision immediately follows the $4.2bn acquisition of Merck KGaA’s Consumer Health division by P&G. Teva’s…

First quarter meeting expectations for Novartis

Switzerland-based pharmaceutical group Novartis has announced today its Q1 2018 results. These have not satisfied investors, indeed Novartis’ shares have lost almost 3% (Zurich). The group’s profits have increased by 22% ($2.03bn), especially thanks to products against cancer and cardiovascular…

Wacker acquires biopharmaceuticals site in Luxembourg

The Germany-based chemical group Wacker Chemie AG has acquired a Dutch site for manufacturing vaccines and microbial products from Luxembourg-based SynCo. The plants’ high output–thanks to two fermentation lines with capacities of 1,500 and 270 liters, will allow Wacker to…

An analysis of German biotech industry

The German economic-financial daily Handelsblatt yesterday published a long article about the current state of the German biotech industry. 657 biotechs are currently operating in Germany–vs 641 in 2016–and they together delivered revenues slightly exceeding €4bn in 2017, which represents…

Sanofi sells 12 drugs to Cooper-Vemedia for €158m

The Belgian daily der Standard has reported that Sanofi has sold 12 brands to Cooper-Vemedia for €158m. The sale is part of Sanofi’s strategy to simplify its product portfolio and fund its recent acquisitions. Cooper-Vemedia belongs to private equity Charterhouse…

New FDA approval for US-based biotech Ultragenyx

The Novato, California-based biotech Ultragenyx yesterday announced, before Wall Street opened, that its investigational therapy Crysvita (burosumab) has obtained the FDA approval for the treatment of X–Linked Hypophosphatemia (XLH), a rare condition. XLH is a serious disease affecting bones, which…

Positive first quarter for Johnson & Johnson

US-based pharmaceutical giant Johnson & Johnson has reported today, before Wall Street opened, its first-quarter results, which are beyond analyst’s expectations. Revenues in 2017 reached $20bn and profits were $2.06bn, whereas analysts expected, respectively, $19.5bn and $2.0bn. The good performance…

Advent offers €1.919bn for Sanofi’s Zentiva

Private equity Advent International has announced today in a press release that it is in exclusive talks with Sanofi to acquire Zentiva, the French company’s arm that markets generics all over Europe. Advent has offered Sanofi €1.919bn. Advent International, which…

Wacker acquisisce un sito per prodotti biofarmaceutici nel Lussenburgo

Bristol-Myers Squibb today reported, before Wall Street opened, detailed results from the Phase III CheckMate-227 clinical trial, testing Opdivo (nivolumab) low-dose 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg in patients with non-small cell lung cancer (NSCLC). The results show that…

Why Merck & Co. makes serious bet on Keytruda

The US-based group Merck & Co. is largely focusing on its blockbuster Keytruda, an immunotherapy launched in Q4 2014 that has delivered approximately $5bn revenues since then, $3.8bn of which in 2017, that is as much as 9% of the…

Sanofi invests €350m on new vaccine production plant

France-based Sanofi has confirmed this week a significant €350m (CA$500m) investment to build a vaccine production plant in its plant in Toronto, Canada. The new investment makes the Canadian site one of the main plants of the group, with over…

Intercept shows another significant benefit of Ocaliva to people with PCB

New York-based biotech company Intercept Pharmaceuticals keeps momentum: its shares have risen over 15% since the beginning of the month. Intercept yesterday announced in a press release that the Phase III POISE clinical trial has demonstrated that Ocaliva (obeticholic acid)…

Advent Capital now about to acquire Sanofi’s Zentiva ($2bn)

Advent International is reportedly about to acquire Zentiva, Sanofi’s European arm marketing generics. Advent has beaten its competitor, the investor BC Partners, the Financial Times has reported. Private equities Blackstone and Nordic Capital have already pulled out from the race…

Genevant, a new company focusing on gene therapy

British Columbia, Canada-based Arbutus Biopharma and Switzerland-based Roivant Sciences have established Genevant Sciences. The new company will be based in Massachusetts and will aim to develop novel gene therapies (RNA) that will use Arbutus’ Lipid NanoParticle (LNP) technology to release…

GSK announces sale of rare disease therapies to Orchard Therapeutics

GlaxoSmithKline has sold its rare disease therapy portfolio to Orchard Therapeutics in exchange for 20% of shares in the Anglo-American biotech and royalties on profits delivered by Orchard with GSK’s treatments. GSK’s move allows the UK-based company to focus on…

Chinese biotech sector, leader in CAR-T technology

China has clearly acquired an outstanding position in the CAR-T area, with 116 ongoing clinical trials, versus 96 in the US and 15 in Europe. Chinese researchers are obtaining positive results in the treatment of blood cancers considered incurable before…

Ionis sells NASH therapy to AstraZeneca for $300m

California-based Ionis Pharmaceuticals has announced it has licensed to AstraZeneca its investigational therapy Ionis-AZ6-2.5, developed to treat patients with Non-Alcoholic Steatohepatitis (NASH). This is the third therapy obtained from the partnership between the firms. Under the terms of the agreement,…

New deal for Novartis

It is widely understood that new Novartis CEO Vas Narasimhan has a far more aggressive managerial style than his predecessor Joseph Jiménez. Since Narasimhan was appointed CEO, Novartis has entered into M&A agreements for a total of $25.8bn: it has…

Novartis acquires AveXis for $8.7bn

Novartis has announced it has acquired AveXis for $8.7bn, paying it $218 per share, that is a 88% premium over the company’s closing price on Friday ($115.9). AveXis focuses on gene therapies for the treatment of spinal muscular atrophy and…

Investors reward Intercept Pharmaceuticals again

Intercept Pharmaceuticals is apparently experiencing a positive momentum, following the hardship over the last 8 months, which had caused shares to drop–they have fallen approximately 50% starting from September 2017. The positive phase reflects the New York-based company issuing new…

Rude awakening for immunotherapy sector

Last Friday’s news about the failed Phase III clinical trial with immunotherapy Keytruda in combination with Incyte’s cancer therapy epacadostat not only has wiped $4m from the US biotech’s capitalization over few hours, but has also risen much concern among…

Major restructuring with staff cuts in US for Teva

The Kansas City Business Journal has reported that Teva is in talks with Orlando, Florida-based biotech AssistRX to sell its Overland Park Patient Services & Solutions unit. The arm employs 200 people and provides support to patients with Parkinson’s disease…